en P67: The Effect of Melatonin on EDSS and Fatigue in Multiple Sclerosis تحقیقات پایه در علوم اعصاب Basic research in Neuroscience پژوهشي Research --- Open Access, CC-BY-NC <table border="0" cellpadding="5" cellspacing="2" dir="rtl" id="table_article" style="text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: Tahoma; word-spacing: 0px; orphans: 2; widows: 2; break-inside: avoid !important; background-color: rgb(251, 250, 249); -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" width="100%"> <tbody style="text-align: justify; line-height: 2.2; font-size: 12px; margin-top: 0px; margin-bottom: 0px; break-inside: avoid !important;"> <tr style="break-inside: avoid !important;"> <td class="abstractmed" colspan="2" style="text-align: justify; break-inside: avoid !important;"> <p style="text-align: center; font-size: 12px; margin-top: 0px; margin-bottom: 0px;"><span style="text-align: center; color: rgb(0, 0, 0); font-family: Tahoma; font-size: 12px; background-color: rgb(251, 250, 249);">لطفاً به چکیده انگلیسی مراجعه شود.</span></p> </td> </tr> <tr style="break-inside: avoid !important;"><br> &nbsp; </tr> </tbody> </table> <p style="margin: 12pt 0cm 0pt; text-align: justify; unicode-bidi: embed; direction: ltr;"><font color="#000000"><span style="line-height: 115%; font-family: &quot;Times New Roman&quot;,serif; font-size: 10pt; mso-ascii-theme-font: major-bidi; mso-fareast-font-family: Calibri; mso-hansi-theme-font: major-bidi; mso-bidi-theme-font: major-bidi;">Multiple Sclerosisis (MS) is a common demylinating disease of CNS that inflammation and stress oxidative processes have an important role in clinical courses and progression of it. Suppressing the antigen-presenting capacity of glial cells seems a convinient way of reducing inflammatory activity in MS. The aim of the present study was to determine the anti-inflamatory effects of Melatonin on fatigue and EDSS in MS.</span><b><span style="line-height: 115%; font-family: &quot;Times New Roman&quot;,serif; font-size: 10pt; mso-ascii-theme-font: major-bidi; mso-fareast-font-family: &quot;Times New Roman&quot;; mso-hansi-theme-font: major-bidi; mso-bidi-theme-font: major-bidi; mso-bidi-language: AR-SA;"> </span></b><span style="line-height: 115%; font-family: &quot;Times New Roman&quot;,serif; font-size: 10pt; mso-ascii-theme-font: major-bidi; mso-fareast-font-family: Calibri; mso-hansi-theme-font: major-bidi; mso-bidi-theme-font: major-bidi; mso-bidi-language: AR-SA;">In a double-blind, placebo-controlled exploratory study, 62 patients with relapsing remitting MS were randomised to oral Melatonin 3 mg or placebo daily for 8 weeks. Scale of Fatigue in MS and disability was studied by assessing FSS (Fatigue Severity Scale) and EDSS (Expanded Disability Status Scale) on weeks 1 and 8.</span><b><span style="line-height: 115%; font-family: &quot;Times New Roman&quot;,serif; font-size: 10pt; mso-ascii-theme-font: major-bidi; mso-fareast-font-family: &quot;Times New Roman&quot;; mso-hansi-theme-font: major-bidi; mso-bidi-theme-font: major-bidi; mso-bidi-language: AR-SA;"> </span></b></font><span style="color: rgb(41, 37, 38); line-height: 115%; font-family: &quot;Times New Roman&quot;,serif; font-size: 10pt; mso-ascii-theme-font: major-bidi; mso-fareast-font-family: Calibri; mso-hansi-theme-font: major-bidi; mso-bidi-theme-font: major-bidi;">47 patient in intervention group and 15 patient in placebo group completed the study.</span><span style="color: black; line-height: 115%; font-family: &quot;Times New Roman&quot;,serif; font-size: 10pt; mso-ascii-theme-font: major-bidi; mso-fareast-font-family: Calibri; mso-hansi-theme-font: major-bidi; mso-bidi-theme-font: major-bidi;"> In patient, treatment with Melatonin produced a significant decrease in FSS vs placebo patienta.Although in control group<span dir="RTL" lang="FA">،</span>the average of FSS was 35.866 that after intervention<span dir="RTL" lang="FA">،</span> was 41.Because the score of placebo patient is near or upper than 36<span dir="RTL" lang="FA"> ،</span></span><font color="#000000"><span style="line-height: 115%; font-family: &quot;Times New Roman&quot;,serif; font-size: 10pt; mso-ascii-theme-font: major-bidi; mso-fareast-font-family: &quot;Times New Roman&quot;; mso-hansi-theme-font: major-bidi; mso-bidi-theme-font: major-bidi; mso-bidi-language: AR-SA;">this study suggested that Melatonin has a significant effect on improving and decreasing fatigue in MS. Also in this study the average of early EDSS was 2.96 in intervention group and 4.86 in placebo group and after treatment with melatonin was 2.8 and 4.53 in intervention and placebo group respectively.<b> </b>This study suggested that melatonin has a weak effect on improvement of disability and EDSS in MS.<b> </b></span><span style="line-height: 115%; font-family: &quot;Times New Roman&quot;,serif; font-size: 10pt; mso-ascii-theme-font: major-bidi; mso-fareast-font-family: Calibri; mso-hansi-theme-font: major-bidi; mso-bidi-theme-font: major-bidi; mso-bidi-language: AR-SA;">Our study shows that use of melatonin along side of First-line drugs such as mitoxantrone<span dir="RTL" lang="AR-SA">،</span> IFN &ndash; B or glatimer acetate can improve fatigue in patient with MS.</span></font></p> EDSS, Fatigue, Melatonin, Multiple Sclerosis 98 98 http://shefayekhatam.ir/browse.php?a_code=A-10-24-1228&slc_lang=en&sid=1 Farzaneh Fuladi Targhi Farzaneh Fuladi Targhi farzaneh.fuladi@yahoo.com 100319475328460014747 100319475328460014747 Yes Neurology Department, Medicine College, Medical University, Arak, Iran Neurology Department, Medicine College, Medical University, Arak, Iran Fardin Faraji Fardin Faraji 100319475328460014748 100319475328460014748 No Neurology Department, Medicine College, Medical University, Arak, Iran Neurology Department, Medicine College, Medical University, Arak, Iran Ali Akbar Maleki Rad Ali Akbar Maleki Rad 100319475328460014749 100319475328460014749 No Neurology Department, Medicine College, Medical University, Arak, Iran Neurology Department, Medicine College, Medical University, Arak, Iran Keyvan Ghasami Keyvan Ghasami 100319475328460014750 100319475328460014750 No Neurology Department, Payame-Noor University, Arak, Iran Neurology Department, Payame-Noor University, Arak, Iran Afsoon Talaie Afsoon Talaie 100319475328460014751 100319475328460014751 No Neurology Department, Payame-Noor University, Arak, Iran Neurology Department, Payame-Noor University, Arak, Iran